Pheast Therapeutics
Pheast Therapeutics, Inc.
Pheast Therapeutics, Inc. is a preclinical-stage biotechnology company focused on developing novel immuno-oncology therapies. The company is pioneering a new approach to cancer treatment by targeting innate immune evasion pathways, specifically harnessing the power of macrophages to recognize and eliminate cancer cells. Pheast's innovative approach aims to address the limitations of current immunotherapies and offer solutions for aggressive cancers.
Products & Team
PHST001
PHST001 is an innovative monoclonal antibody targeting CD24, a "don't eat me" signal expressed by various cancer cells, including those found in ovarian and triple-negative breast cancer. By specifically binding to and blocking CD24, PHST001 promotes macrophage-mediated phagocytosis, facilitating the immune system's ability to recognize, engulf, and destroy cancer cells. Preclinical studies have demonstrated the potential of PHST001 to significantly reduce and even eradicate tumors in animal models, highlighting its promise as a novel cancer therapy.
Overcomes immune evasion by blocking the CD24 "don't eat me" signal, potentially leading to tumor shrinkage and eradication in patients with CD24-expressing cancers.
Lack of effective treatment options; resistance to existing immunotherapies; high unmet medical needs in aggressive cancers.